GlassScriptPhysician profile
Rebekah Chen
NPI 1003283672
$14,462.94
in general payments reported to CMS, 2019-2025
37 companies · $5,430 in 2025
The $5,430 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $446 · 2022: $1,614 · 2023: $2,774 · 2024: $4,198 · 2025: $5,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,960.72 |
| Education | $441.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,599.54 | 2021-2025 | Tremfya |
| Abbvie INC. | $1,450.68 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,395.59 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,071.34 | 2022-2024 | Vtama |
| Genzyme Corporation | $1,067.13 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $985.92 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $784.02 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $713.78 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $642.07 | 2023-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $614.94 | 2022-2025 | Sotyktu |
| Organon LLC | $567.88 | 2025 | Vtama, Nexplanon, Hadlima |
| Lilly USA, LLC | $547.30 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $543.67 | 2023-2025 | Zoryve |
| Pfizer INC. | $527.18 | 2021-2025 | |
| Galderma Laboratories, L.P. | $383.77 | 2023-2025 | Nemluvio, Aklief, Oracea |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $358.04 | 2021-2025 | Bimzelx |
| Amgen INC. | $340.47 | 2021-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.16 | 2022-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $80.06 | 2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $71.58 | 2024-2025 | Cabtreo, Arazlo, Jublia |
| Fresenius Kabi USA, LLC | $68.71 | 2023-2024 | Idacio |
| Almirall LLC | $50.72 | 2022 | |
| Blueprint Medicines Corporation | $49.00 | 2023-2024 | Ayvakit |
| Organogenesis INC. | $43.49 | 2025 | Puraply Wound Matrix |
| Helsinn Therapeutics (U.S.), INC. | $36.91 | 2022 | |
| Mission Pharmacal Company | $34.81 | 2022-2023 | Avar |
| Botanix Sb INC | $32.82 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $26.61 | 2023 | |
| Glaxosmithkline, LLC. | $24.57 | 2023 | Shingrix, Arexvy |
| Kyowa Kirin, INC. | $24.36 | 2025 | |
| Nabriva Therapeutics, Plc | $21.76 | 2022 | |
| Strata Skin Sciences, INC. | $19.77 | 2025 | Xtrac |
| Biofrontera INC. | $17.56 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $16.67 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.21 | 2021 | |
| Krystal Biotech INC | $14.85 | 2025 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekah Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.